Literature DB >> 11836446

Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia.

P Vorwerk1, H Wex, B Hohmann, K Mohnike, U Schmidt, U Mittler.   

Abstract

BACKGROUND: Alterations in the insulin-like growth factor (IGF) system have been reported for different tumours. They are of particular interest in the search for new prognostic and therapeutic approaches in cancer. In childhood acute lymphoblastic leukaemia (ALL) the amount of "tumour mass" at diagnosis can exceed 1 kg. To understand the endocrine, paracrine, and autocrine potential of the malignant transformed progenitor cells, the ability of these cells to express components of the IGF system needs to be investigated. AIM: To characterise the expression pattern of genes of the IGF system in malignant lymphoblasts of children suffering from ALL.
METHODS: Reverse transcription polymerase chain reaction of Ficoll separated mononuclear cells from 142 children with ALL, 127 cord blood samples, and 55 blood samples of age matched controls were studied.
RESULTS: The expression of IGF-I, IGF-II, IGF binding protein 5 (IGFBP-5), and CTGF (IGFBP-rP2) was seen in a higher proportion of mononuclear cells of patients with ALL than in controls. Patients with ALL who were in continuous remission had a lower percentage of IGFBP-2 and IGFBP-3 expressing mononuclear cells at diagnosis than did those who developed a relapse. Only malignant lymphoblasts of B cell origin showed expression of CTGF (IGFBP-rP2). Malignant lymphoblasts of T cell origin more often expressed IGFBP-2 and IGFBP-5, whereas IGF-II and IGFBP-3 expression was seen more often in lymphoblasts of B cell origin.
CONCLUSIONS: Malignant lymphoblasts of patients with ALL express components of the IGF system and therefore promote their own growth in an autocrine, paracrine, or endocrine manner. Whether these components will be useful as prognostic factors in the stratification of ALL treatment in children needs to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836446      PMCID: PMC1187145          DOI: 10.1136/mp.55.1.40

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  45 in total

Review 1.  The modular architecture of a new family of growth regulators related to connective tissue growth factor.

Authors:  P Bork
Journal:  FEBS Lett       Date:  1993-07-26       Impact factor: 4.124

2.  The expression of insulin-like growth factors and their binding proteins in normal human lymphocytes.

Authors:  T Nyman; F Pekonen
Journal:  Acta Endocrinol (Copenh)       Date:  1993-02

3.  The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness.

Authors:  S C Davies; J A Wass; R J Ross; A M Cotterill; C R Buchanan; V J Coulson; J M Holly
Journal:  J Endocrinol       Date:  1991-09       Impact factor: 4.286

4.  Human leukemic T and B lymphoblasts produce insulin-like growth factor binding proteins 2 and 4.

Authors:  E K Neely; S D Smith; R G Rosenfeld
Journal:  Acta Endocrinol (Copenh)       Date:  1991-06

5.  A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin.

Authors:  C Lalou; C Lassarre; M Binoux
Journal:  Endocrinology       Date:  1996-08       Impact factor: 4.736

6.  Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5.

Authors:  A Parker; J B Clarke; W H Busby; D R Clemmons
Journal:  J Biol Chem       Date:  1996-06-07       Impact factor: 5.157

7.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen.

Authors:  H Kanety; Y Madjar; Y Dagan; J Levi; M Z Papa; C Pariente; B Goldwasser; A Karasik
Journal:  J Clin Endocrinol Metab       Date:  1993-07       Impact factor: 5.958

8.  The insulin-like growth factor 1 receptor is required for the proliferation of hemopoietic cells.

Authors:  K Reiss; P Porcu; C Sell; Z Pietrzkowski; R Baserga
Journal:  Oncogene       Date:  1992-11       Impact factor: 9.867

9.  Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer.

Authors:  V Papa; B Gliozzo; G M Clark; W L McGuire; D Moore; Y Fujita-Yamaguchi; R Vigneri; I D Goldfine; V Pezzino
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

10.  Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10.

Authors:  D M Bradham; A Igarashi; R L Potter; G R Grotendorst
Journal:  J Cell Biol       Date:  1991-09       Impact factor: 10.539

View more
  13 in total

1.  A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E Rytting; Jitesh D Kawedia; Jordan Basnett; Kirk S Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J Bendall; Deborah Thomas; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia.

Authors:  Olga Sala-Torra; Holly M Gundacker; Derek L Stirewalt; Paula A Ladne; Era L Pogosova-Agadjanyan; Marilyn L Slovak; Cheryl L Willman; Shelly Heimfeld; David H Boldt; Jerald P Radich
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

3.  Effects of insulin-like growth factor-1 on B-cell precursor acute lymphoblastic leukemia.

Authors:  Hiroyuki Yamada; Kazutoshi Iijima; Osamu Tomita; Tomoko Taguchi; Masashi Miharu; Kenichiro Kobayashi; Hajime Okita; Masahiro Saito; Toshiaki Shimizu; Nobutaka Kiyokawa
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

4.  Insulin-like growth factor-binding protein 4 in children with acute lymphoblastic leukemia.

Authors:  Heike Wex; Dörte Ahrens; Bianka Hohmann; Antje Redlich; Uwe Mittler; Peter Vorwerk
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

5.  Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.

Authors:  Hemant K Bid; Jun Zhan; Doris A Phelps; Raushan T Kurmasheva; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2011-12-21       Impact factor: 6.261

6.  Insulin-like growth factor 2 modulates murine hematopoietic stem cell maintenance through upregulation of p57.

Authors:  Dolly D Thomas; Andreia Gianotti Sommer; Alejandro B Balazs; Isabel Beerman; George J Murphy; Derrick Rossi; Gustavo Mostoslavsky
Journal:  Exp Hematol       Date:  2016-02-10       Impact factor: 3.084

7.  Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Authors:  E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Christopher L Morton; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Catherine Billups; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-12-22       Impact factor: 3.167

8.  AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia.

Authors:  Gilles M Leclerc; Guy J Leclerc; Guilian Fu; Julio C Barredo
Journal:  J Mol Signal       Date:  2010-09-23

Review 9.  Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Authors:  Margaret E Macy; Kelly K Sawczyn; Timothy P Garrington; Douglas K Graham; Lia Gore
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

10.  LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor.

Authors:  Lihua Ying; Agatha Lau; Cristina M Alvira; Robert West; Gordon M Cann; Bin Zhou; Caroline Kinnear; Eric Jan; Peter Sarnow; Matt Van de Rijn; Marlene Rabinovitch
Journal:  J Cell Sci       Date:  2009-04-14       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.